Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Food or edible as carrier for pharmaceutical
Reexamination Certificate
1999-06-23
2003-10-28
Naff, David M. (Department: 1651)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Food or edible as carrier for pharmaceutical
C424S401000, C424S439000, C424S070100, C424S094100, C424S094400, C424S094500, C424S094600, C435S180000, C435S183000, C435S189000, C435S193000, C435S195000, C510S392000, C510S530000, C514S002600, C530S402000, C530S815000
Reexamination Certificate
active
06638526
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a polypeptide-polymer conjugate wherein the polymer is a graft, block, alternate, or random co-polymer coupled to the surface of the polypeptide. The invention also relates to industrial compositions and products comprising a conjugate of the invention, the use of a polypeptide-polymer conjugate of the invention for reducing the allergenicity of industrial compositions and products, and finally a method for reducing the allergenicity of polypeptides.
BACKGROUND OF THE INVENTION
For both medical and industrial applications the use of polypeptides, including enzymes, are well-known in the art. As polypeptides may potentially cause an undesired immune response—dependent on the way of challenge—typically an IgG and/or IgE response, techniques for reducing it have been developed during the last three decades.
One technique is the coupling technique where a number of polymeric molecules are coupled to the polypeptide in question. When using this technique the immune system have difficulties recognizing the epitopes (on the polypeptide's surface) responsible for the formation of antibodies, thereby reducing the immune response.
For polypeptides introduced directly into the circulatory system of the human body to give a particular physiological effect (i.e. pharmaceuticals) the typical potential immune response is an IgG and/or IgM response, while polypeptides which are inhaled through the respiratory system (i.e. industrial polypeptide) potentially may cause an IgE response (i.e. allergic response).
One of the theories explaining the reduced immune response is that the polymeric molecule(s) shield(s) epitope(s) on the surface of the polypeptide responsible for the immune response leading to antibody formation. Another theory or at least a partial factor is that the heavier the conjugate is the more reduced immune response is obtained.
Typically the polymers used for coupling to polypeptide to form conjugates are homopolymers, i.e. consisting of one repeating unit, e.g., ethylene oxide (EO), especially polyethylene glycol (PEG), or propylene oxide (PO), especially polypropylene glycol (PPG). Sacchareides, such as dextran have also been used.
U.S. Pat. No. 4,179,337 concerns non-immunogenic polypeptides, such as enzymes and peptide hormones coupled to polyethylene glycol (PEG) or polypropylene glycol (PPG).
WO 96/17929 (Novo Nordisk A/S) concerns modified polypeptide conjugates coupled to polymeric molecules, in particular polyethylene glycol (PEG).
SUMMARY OF THE INVENTION
The present invention relates to a polypeptide-polymer conjugate suitable for industrial applications and incorporation as active ingredients in industrial products.
The present inventors have found that when coupling graft, block, alternate, or random co-polymers with the general formula:
EO
x
PO
y
(I)
wherein x=1−99%, y=1−99%, and x+y=100% covalently to a parent polypeptide, used for industrial application, the respiratory allergenicity is reduced when compared to the parent enzyme and even when compared to a corresponding conjugate coupled with PEG or other homopolymers.
In a second aspect the invention relates to compositions for use in industrial products comprising a conjugate of the invention.
In a third aspect the invention relates to a method for reducing the allergenicity of polypeptides.
Industrial Polypeptides
Polypeptides used for industrial applications often have an enzymatic and/or anti-microbial activity. Industrial polypeptides are (in contrast to pharmaceutical polypeptides) not intended to be introduced into the circulatory system of the body.
Therefore, it is not very likely that industrial polypeptides, such as enzymes, used as active ingredients in industrial compositions and/or products (defined below), such as detergents, such as laundry and dish washing detergens, food or feed additives, including additives for bread making, composition for treating textiles, and personal care products, including cosmetics, come into direct contact with the circulatory system of the body of humans or animals, as such polypeptides (or products comprising such polypeptides) are not injected (or the like) into the bloodstream.
Thus, in the case of the industrial polypeptide the potential risk is respiratory allergy (i.e. IgE response) as a consequence of inhalation of polypeptides through the respiratory passage.
In the context of the present invention “industrial polypeptides” are defined as polypeptides, including peptides, proteins and/or enzymes, which are not intended to be introduced into the circulatory system of the body of humans and/or animals.
Examples of such polypeptide include polypeptides with enzymatic activity as defined below.
The invention also relates to industrial compositions and products having reduced respiratory allergenicity.
Furthermore, the invention relates to the use of a polypeptide-polymer conjugate of the invention for reducing the respiratory allergenicity of industrial composition and products.
Finally the invention relates to a method for reducing the allergenicity of polypeptides, in particular enzymes, by coupling one or more a graft, block, alternate, or random co-polymer to a parent unmodified polypeptide.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 6114509 (2000-09-01), Olsen et al.
patent: 6201110 (2001-03-01), Olsen et al.
patent: 6245901 (2001-06-01), Osten et al.
patent: WO 89/01033 (1989-02-01), None
patent: WO 94/13311 (1994-06-01), None
patent: WO 96/17929 (1996-06-01), None
patent: WO 96/40792 (1996-12-01), None
patent: WO 97/24421 (1997-07-01), None
patent: WO 97/30148 (1997-08-01), None
Deussen Heinz-Josef
Fatum Tine Muxoll
Olsen Arne Agerlin
Roggen Erwin Ludo
Lambiris Elias J.
Naff David M.
Novozymes A/S
LandOfFree
Polypeptides conjugated to copolymers of ethylene oxide and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptides conjugated to copolymers of ethylene oxide and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptides conjugated to copolymers of ethylene oxide and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3135775